Sanofi completes closing for potential vaccine against extraintestinal pathogenic E.coli
Paris: Sanofi has announced the completion of closing for its collaborative agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) (ExPEC9V).Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis, causing...
Paris: Sanofi has announced the completion of closing for its collaborative agreement with Janssen Pharmaceuticals, Inc., a Johnson & Johnson company to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) (ExPEC9V).
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis, causing approximately 10 million cases of invasive ExPEC disease annually, worldwide. It is associated with increased hospitalizations, mortality and antimicrobial resistance resulting in significant healthcare and societal costs.
Thomas Triomphe, Executive Vice President, Vaccines, Sanofi said, “At Sanofi, we believe in the power of partnership to deliver true innovation. In this case, we’re bringing together Janssen’s robust science and Sanofi’s worldwide manufacturing footprint and expertise in launching innovative vaccines. We look forward to delivering this potential first-in-class vaccine designed to help older adults around the world live longer, healthier lives.”
ExPEC9V is currently being assessed via the Phase 3 E.mbrace trial which continues to enroll patients.
Read also: Sanofi considers listing consumer unit late next year
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd